CN101632779B - Medicament for treating labyrinthine syndrome and preparation method thereof - Google Patents
Medicament for treating labyrinthine syndrome and preparation method thereof Download PDFInfo
- Publication number
- CN101632779B CN101632779B CN2008100554717A CN200810055471A CN101632779B CN 101632779 B CN101632779 B CN 101632779B CN 2008100554717 A CN2008100554717 A CN 2008100554717A CN 200810055471 A CN200810055471 A CN 200810055471A CN 101632779 B CN101632779 B CN 101632779B
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- bulbus fritillariae
- angelicae sinensis
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 208000011580 syndromic disease Diseases 0.000 title abstract description 4
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims abstract description 9
- 229940097275 indigo Drugs 0.000 claims abstract description 9
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 241000217407 Margaritifera Species 0.000 claims description 24
- 241000756943 Codonopsis Species 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims description 14
- 208000027530 Meniere disease Diseases 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 241000207929 Scutellaria Species 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 3
- 208000026435 phlegm Diseases 0.000 abstract description 3
- 210000000952 spleen Anatomy 0.000 abstract description 3
- 208000004880 Polyuria Diseases 0.000 abstract description 2
- 230000035619 diuresis Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000489492 Arisaema Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 1
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 241000935235 Fritillaria meleagris Species 0.000 abstract 1
- 208000002173 dizziness Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 208000009205 Tinnitus Diseases 0.000 description 8
- 231100000886 tinnitus Toxicity 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 206010011878 Deafness Diseases 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 231100000895 deafness Toxicity 0.000 description 6
- 208000016354 hearing loss disease Diseases 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000004334 sorbic acid Substances 0.000 description 4
- 235000010199 sorbic acid Nutrition 0.000 description 4
- 229940075582 sorbic acid Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- -1 hydroxypropyl Chemical group 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010029864 nystagmus Diseases 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 208000008016 pathologic nystagmus Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a medicament for treating labyrinthine syndrome and a preparation method thereof. The medicament is prepared from Chinese thorowax root, baical skullcap root, natural indigo, unibract fritillary bulb, Chinese angelica, pilose asiabell root, nacre, pedate pinallia jackinthepulpit rhizome and the like. The medicament has the effects of dispersing the spleen and invigorating the stagnated liver-energy, clearing away heat, promoting diuresis and resolving phlegm. Clinical experiments prove that the medicament can treat the labyrinthine syndrome effectively.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of Meniere disease and preparation method thereof, belong to field of Chinese herbal.
Background technology
Menieres disease is a kind of disease of inner ear with hydrolabyrinth.Primary disease is a main clinical manifestation with sudden dizzy, tinnitus, deafness or nystagmus, and dizzy have tangible stage of attack and an intermission.Patient's majority is a middle age, patient's sex no significant difference, and the patient who showed effect first before 50 years old accounts for 65%, and the most patient monaural is ill.
Each one is not quite similar the symptom of Menieres disease, and the cardinal symptom of stage of attack is: outbreak can show effect suddenly at any time, even also can show effect after sleeping.Modal symptom is: when patient opens eyes, the sensation house or on every side object rotating, then conscious health can make patient fall down to the ground suddenly in rotation when closing one's eyes when the dizzy oncoming force is fierce.Between stage of attack patient open eyes or rotation head then symptom can increase the weight of, repose so most patient is closed order, head and health all dare not rotate.Most patients one-sided tinnitus and deafness occur when outbreak, minority is a bilateral.About 25% patient is existing tinnitus and deaf the appearance before outbreak, and in the outbreak postemphasis.
All the other about 25% just engender tinnitus or deafness after outbreak.Deafness belongs to nerve, and the tinnitus of showing effect when violent is also increased the weight of, during outbreak patient often with dare not open eyes, feel sick, the most a series of symptoms such as on the low side of vomiting, pale complexion, perspiration even diarrhoea, blood pressure.Part patient is with headache; General patient's Consciousness.
Stage of attack transfers the intermission to two kinds of forms: a kind of is dizzy and simultaneous phenomenon suddenly disappears, and a kind of is dizzyly to gradually become giddy and disappear gradually.The intermission of Meniere is different in size, and from the several months to the several years, each outbreak and degree are also different.And audition is faded along with the increase of attack times, causes deafness at last.
From ancient times to the present there are many doctors to study the treatment Menieres disease.Ancient times, the doctor once guessed the similar glaucomatous high intraocular pressure of the dizzy pathology of Menieres disease.Inquire into the glaucomatous mechanism of treatment and treat U.S. Nissl syndrome, the result has failed.Carry out operative treatment, the scope of application is very little, and effect is undesirable.Infusion treatment can only the respite symptom.The long-term western medicine that adopts can not fundamentally be cured.Dizzy academic the summary in the meeting in the world, conference the authoritative sources say: do not find effective medicine so far.Operation is based on the decompression by fenestration alleviation.So Menieres disease remains universally acknowledged difficult disease.
Summary of the invention
The invention provides a kind of medicine for the treatment of Meniere disease, this medicine is made by following bulk drugs:
Radix Bupleuri 5-20 Radix Scutellariae 5-20 Indigo Naturalis 5-20 Bulbus Fritillariae Cirrhosae 5-20 Radix Angelicae Sinensis 5-20 Radix Codonopsis 5-20 Concha Margaritifera 5-20 Rhizoma Arisaematis 2-8.
The crude drug part by weight of medicine of the present invention is preferably:
Radix Bupleuri 10-15 Radix Scutellariae 10-15 Indigo Naturalis 10-15 Bulbus Fritillariae Cirrhosae 10-15 Radix Angelicae Sinensis 10-15 Radix Codonopsis 10-15 Concha Margaritifera 10-15 Rhizoma Arisaematis 3-6.
More preferably:
Radix Bupleuri 10 Radix Scutellariaes 15 Indigo Naturaliss 10 Bulbus Fritillariae Cirrhosaes 15 Radix Angelicae Sinensis 10 Radix Codonopsis 15 Concha Margaritiferas 10 Rhizoma Arisaematiss 3.
Or:
Radix Bupleuri 15 Radix Scutellariaes 10 Indigo Naturaliss 15 Bulbus Fritillariae Cirrhosaes 10 Radix Angelicae Sinensis 15 Radix Codonopsis 10 Concha Margaritiferas 15 Rhizoma Arisaematiss 6.
Or:
Radix Bupleuri 10 Radix Scutellariaes 10 Indigo Naturaliss 10 Bulbus Fritillariae Cirrhosaes 10 Radix Angelicae Sinensis 10 Radix Codonopsis 10 Concha Margaritiferas 10 Rhizoma Arisaematiss 3.
Or:
Radix Bupleuri 15 Radix Scutellariaes 15 Indigo Naturaliss 15 Bulbus Fritillariae Cirrhosaes 15 Radix Angelicae Sinensis 15 Radix Codonopsis 15 Concha Margaritiferas 15 Rhizoma Arisaematiss 6.
Concha Margaritifera in the above-mentioned raw materials medicine can use the Concha Haliotidis with weight portion to replace, and Bulbus Fritillariae Cirrhosae can use the Bulbus Fritillariae Thunbergii with weight portion to replace.
Medicament form of pharmaceutical preparation of the present invention is a mixture, capsule, tablet, granule, powder or pill, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic etc., filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc., disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc., lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc., suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc., binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc., sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc., correctives comprises: sweeting agent and various essence, and antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, the acetic acid chloroethene is fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods.
Preferably, the preparation method of drug mixture of the present invention may further comprise the steps and makes:
1) take by weighing Concha Margaritifera in proportion, Rhizoma Arisaematis, after being decocted first 1 hour, the Radix Bupleuri of additional proportion amount, Radix Scutellariae, Bulbus Fritillariae Cirrhosae, Radix Angelicae Sinensis, decoct 1 hour again after, filter filtrate for later use;
2) take by weighing Indigo Naturalis in proportion, after decocting a drug wrapped 1 hour, filter, merge, filter, concentrate, add antiseptic with step 1) gained decocting liquid, correctives, stir, leave standstill, embedding, sterilization promptly.
This disease belongs to motherland's medical science " dizzy ", " tinnitus, deafness " category.Pharmaceutical composition of the present invention is guidance with the theory of Chinese medical science, thinks that the generation of primary disease and liver, spleen, phlegm-damp have confidential relation, constantly sums up the screening and optimizing medicine and forms, and finally drafts we.The merit that complete square long memorial liver spleen, clearing away heat-damp and promoting diuresis altogether reduce phlegm has good effect to Meniere.
The consumption of Chinese medicine composition of the present invention by the crude drug gross weight, is 70-115 gram/day, but takes every day once, preferably divides and takes for 2-3 time.
The specific embodiment
Following embodiment is used to illustrate the preparation of medicine of the present invention, but it can not constitute any restriction to scope of the present invention.
Embodiment 1
The preparation of mixture
Prescription:
Radix Bupleuri 10g Radix Scutellariae 10g Indigo Naturalis 10g Bulbus Fritillariae Cirrhosae 10g Radix Angelicae Sinensis 10g Radix Codonopsis 10g Concha Margaritifera 10g Rhizoma Arisaematis 3g.
Preparation method:
1) take by weighing Concha Margaritifera in proportion, Rhizoma Arisaematis, after being decocted first 1 hour, the Radix Bupleuri of additional proportion amount, Radix Scutellariae, Bulbus Fritillariae Cirrhosae, Radix Angelicae Sinensis, decoct 1 hour again after, filter filtrate for later use;
2) take by weighing Indigo Naturalis in proportion, after decocting a drug wrapped 1 hour, filter,, concentrate, add sorbic acid 0.2g with step 1) gained decocting liquid mixing, sucrose 20g, stir, leave standstill, embedding, sterilization promptly.
Embodiment 2
The preparation of mixture
Prescription:
Radix Bupleuri 100g Radix Scutellariae 150g Indigo Naturalis 100g Bulbus Fritillariae Cirrhosae 150g Radix Angelicae Sinensis 100g Radix Codonopsis 150g Concha Margaritifera 100g Rhizoma Arisaematis 30g.
Preparation method:
1) take by weighing Concha Margaritifera in proportion, Rhizoma Arisaematis, after being decocted first 1 hour, the Radix Bupleuri of additional proportion amount, Radix Scutellariae, Bulbus Fritillariae Cirrhosae, Radix Angelicae Sinensis, decoct 1 hour again after, filter filtrate for later use;
2) take by weighing Indigo Naturalis in proportion, after decocting a drug wrapped 1 hour, filter,, concentrate, add sorbic acid 3g with step 1) gained decocting liquid mixing, sucrose 200g, stir, leave standstill, embedding, sterilization promptly.
Embodiment 3
The preparation of mixture
Prescription:
Radix Bupleuri 15g Radix Scutellariae 15g Indigo Naturalis 15g Bulbus Fritillariae Cirrhosae 15g Radix Angelicae Sinensis 15g Radix Codonopsis 15 Concha Margaritifera 15g Rhizoma Arisaematis 6g.
Preparation method:
1) take by weighing Concha Margaritifera in proportion, Rhizoma Arisaematis, after being decocted first 1 hour, the Radix Bupleuri of additional proportion amount, Radix Scutellariae, Bulbus Fritillariae Cirrhosae, Radix Angelicae Sinensis, decoct 1 hour again after, filter filtrate for later use;
2) take by weighing Indigo Naturalis in proportion, after decocting a drug wrapped 1 hour, filter,, concentrate, add sorbic acid 0.3g with step 1) gained decocting liquid mixing, sucrose 21g, stir, leave standstill, embedding, sterilization promptly.
Embodiment 4:
The preparation of tablet
Prescription:
Radix Bupleuri 15g Radix Scutellariae 10g Indigo Naturalis 15g Bulbus Fritillariae Cirrhosae 10g Radix Angelicae Sinensis 15g Radix Codonopsis 10g Concha Margaritifera 15g Rhizoma Arisaematis 6g.
Preparation method:
Preparation method is made tablet routinely.
Embodiment 5
The preparation of capsule
Prescription:
Radix Bupleuri 10g Radix Scutellariae 10g Indigo Naturalis 10g Bulbus Fritillariae Cirrhosae 10g Radix Angelicae Sinensis 10g Radix Codonopsis 10g Concha Margaritifera 10g Rhizoma Arisaematis 3g.
Preparation method:
Preparation method is made capsule routinely.
Embodiment 6
The preparation of granule
Prescription:
Radix Bupleuri 15g Radix Scutellariae 15g Indigo Naturalis 15g Bulbus Fritillariae Cirrhosae 15g Radix Angelicae Sinensis 15g Radix Codonopsis 15 Concha Margaritifera 15g Rhizoma Arisaematis 6g.
Preparation method:
Preparation method is made capsule routinely.
Experimental example
For illustrating the activity of traditional Chinese medicine composition for treating Meniere disease of the present invention, use mixture (to call medicine of the present invention in the following text) to carry out following clinical trial according to embodiment 1 preparation.
1 clinical data
1.1 physical data: this is organized whole cases and is 15 years out-patients of inventor, and totally 90 examples all are diagnosed as Meniere's disease through the doctor trained in Western medicine systems inspection, are divided into the therapeutic combination matched group at random.Matched group 40 examples, wherein male 22 examples, women 18 examples, year at age 12～48 (average 33).50 examples are organized in treatment, wherein male 28 examples, women 22 examples, year at age 11～47 (average 34).Two groups of MethodsThe cases enrolled are analyzed no significant difference (P＞0.05) by statistics.
1.2 diagnostic criteria: (1) repeatedly, break out acutely dizzy, auditory dysesthesia and tinnitus, companion's autonomic nervous dysfunction symptom goes out as nausea and vomiting antiperspirant; (2) occurrence law horizontal nystagmus between stage of attack.(3) there is the obvious catabasis.(4) the no abnormal discovery of neurologic check.(5) check blood pressure, routine blood test before the treatment, cervical vertebra X line or CT examination are got rid of hypertension, cervical spondylosis, vertebra one basilar artery system angiopathy, cerebral arteriosclerosis, tumor, anemia and serious hematopathy.
2 Therapeutic Method
2.1 Therapeutic Method
Matched group is used tranquilizer, vasodilator or dehydrant according to patient's clinical manifestation.Stable: 2.5-5mg, every day 3 times; Nicotinic acid: 50-100mg, every day 3 times; Acetazolamide: 250mg/ time, per 6 hours 1 time; Acute attack stage adopts 0.1% procaine, presses 1.5mg/kg and calculates, and is dissolved in 5% glucose solution intravenous drip.
The treatment group adds takes 1 dose of medicine of the present invention every day, take at twice, the course of treatment same matched group.
2.2 efficacy assessment standard
Curative effect determinate standard: recovery from illness: dizzy and tinnitus disappears, and auditory rehabilitation is normal, health check-up: nystagmus disappears, and follows up a case by regular visits to not recurrence in half a year; Take a turn for the better: clinical symptoms is improved; Invalid: clinical symptoms does not have change, and sign is the same.
2.3 statistical analysis adopts the SPSS13 statistical analysis software to analyze, enumeration data adopts x2 to analyze, with P＜0.05 standard of significant difference the most.
3 results
3.1 efficacy result
Treatment group curative effect comparative result sees Table 1, and by table as seen, it is 92.5% that clinical total effective rate is organized in treatment, is significantly higher than matched group.
Table 1 liang group clinical efficacy comparative result n (%)
*Compare P＜0.05 with matched group
3.2 a situation arises in untoward reaction
The treatment group is not found obvious adverse reaction, and pernicious vomiting 4 examples appear in matched group.
4 conclusions
Medicine to sum up of the present invention can effectively be treated Meniere disease, and western medicine does not have obvious adverse reaction relatively.
Claims (8)
1. a medicine for the treatment of Meniere disease is characterized in that, this medicine is made by following bulk drugs:
Radix Bupleuri 5-20 Radix Scutellariae 5-20 Indigo Naturalis 5-20 Bulbus Fritillariae Cirrhosae 5-20 Radix Angelicae Sinensis 5-20
Radix Codonopsis 5-20 Concha Margaritifera 5-20 Rhizoma Arisaematis 2-8.
2. medicine as claimed in claim 1 is characterized in that, this medicine is made by following bulk drugs:
Radix Bupleuri 10-15 Radix Scutellariae 10-15 Indigo Naturalis 10-15 Bulbus Fritillariae Cirrhosae 10-15 Radix Angelicae Sinensis 10-15
Radix Codonopsis 10-15 Concha Margaritifera 10-15 Rhizoma Arisaematis 3-6.
3. medicine as claimed in claim 1 is characterized in that, this medicine is made by following bulk drugs:
Radix Bupleuri 10 Radix Scutellariaes 15 Indigo Naturaliss 10 Bulbus Fritillariae Cirrhosaes 15 Radix Angelicae Sinensis 10 Radix Codonopsis 15
Concha Margaritifera 10 Rhizoma Arisaematiss 3.
4. medicine as claimed in claim 1 is characterized in that, this medicine is made by following bulk drugs:
Radix Bupleuri 15 Radix Scutellariaes 10 Indigo Naturaliss 15 Bulbus Fritillariae Cirrhosaes 10 Radix Angelicae Sinensis 15 Radix Codonopsis 10
Concha Margaritifera 15 Rhizoma Arisaematiss 6.
5. medicine as claimed in claim 1 is characterized in that, this medicine is made by following bulk drugs:
Radix Bupleuri 10 Radix Scutellariaes 10 Indigo Naturaliss 10 Bulbus Fritillariae Cirrhosaes 10 Radix Angelicae Sinensis 10 Radix Codonopsis 10
Concha Margaritifera 10 Rhizoma Arisaematiss 3.
6. medicine as claimed in claim 1 is characterized in that, this medicine is made by following bulk drugs:
Radix Bupleuri 15 Radix Scutellariaes 15 Indigo Naturaliss 15 Bulbus Fritillariae Cirrhosaes 15 Radix Angelicae Sinensis 15 Radix Codonopsis 15
Concha Margaritifera 15 Rhizoma Arisaematiss 6.
7. as each described medicine among the claim 1-6, it is characterized in that Concha Margaritifera can use the Concha Haliotidis with weight portion to replace in the described crude drug, Bulbus Fritillariae Cirrhosae can use the Bulbus Fritillariae Thunbergii with weight portion to replace.
8. as each described medicine among the claim 1-6, it is characterized in that the preparation formulation of described medicine is mixture, capsule, tablet, granule, powder or pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100554717A CN101632779B (en) | 2008-07-25 | 2008-07-25 | Medicament for treating labyrinthine syndrome and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100554717A CN101632779B (en) | 2008-07-25 | 2008-07-25 | Medicament for treating labyrinthine syndrome and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101632779A CN101632779A (en) | 2010-01-27 |
| CN101632779B true CN101632779B (en) | 2011-05-04 |
Family
ID=41592214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100554717A Expired - Fee Related CN101632779B (en) | 2008-07-25 | 2008-07-25 | Medicament for treating labyrinthine syndrome and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101632779B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1155424A (en) * | 1996-01-20 | 1997-07-30 | 赵云高 | Medicine for treating Meniere's disease |
| CN1559594A (en) * | 2004-03-12 | 2005-01-05 | 陈世孝 | Chinese medicine for treating epicophosis, sonitus |
-
2008
- 2008-07-25 CN CN2008100554717A patent/CN101632779B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1155424A (en) * | 1996-01-20 | 1997-07-30 | 赵云高 | Medicine for treating Meniere's disease |
| CN1559594A (en) * | 2004-03-12 | 2005-01-05 | 陈世孝 | Chinese medicine for treating epicophosis, sonitus |
Non-Patent Citations (2)
| Title |
|---|
| 李学仁.《浅谈美尼尔氏病的辨证论治》.《中西医结合杂志》.1985,第5卷(第1期),51-52. * |
| 杜婴.《中医治疗眩晕的研究进展》.《2005全国中医脑病学术研讨会》.2005,441-442. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101632779A (en) | 2010-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101129609A (en) | Chrysanthemum powder for improving eyesight | |
| CN101607036B (en) | Application of Chinese medicinal composition on in preparing medicament for treating depression | |
| CN101530579B (en) | A pharmaceutical composition for soothing the nerves | |
| CN101584796B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating melancholia | |
| CN101816712B (en) | Chinese medicinal composition for treating trigeminal neuralgia | |
| CN103341096A (en) | Medicine for treating hyperplasia of mammary glands and preparation method thereof | |
| CN103341074A (en) | Application of Yixuanning granules in preparation of medicaments for treating insomnia | |
| CN101632779B (en) | Medicament for treating labyrinthine syndrome and preparation method thereof | |
| CN104784667A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN107898960A (en) | A kind of herbal mixture preparation method with the turbid effect of benefiting intelligence of tonifying Qiization | |
| CN106237268A (en) | One treats schizoid pharmaceutical composition and application thereof | |
| CN103495124B (en) | Traditional Chinese medicine decoction for treating Meniere's disease | |
| CN101313990B (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| CN105435048A (en) | Traditional Chinese medicine for treatment of thyroid tumor | |
| CN104274783A (en) | Traditional Chinese medicine for treating cough | |
| CN103933169B (en) | A kind of Chinese medicine composition for fumigation treatment deafness and tinnitus and its preparation method and application | |
| CN103127413B (en) | Pharmaceutical preparation for treating coronary diseases | |
| CN107753664A (en) | A kind of Chinese medicine composition for treating allergic rhinitis and preparation method thereof | |
| CN103055133A (en) | Traditional Chinese medicine for treating hypertension and hyperlipidemia and preparation method of traditional Chinese medicine | |
| CN101683458B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating vertigo | |
| CN101559174A (en) | Specific pure traditional Chinese medicine preparation for curing and preventing Meniere's syndrome and preparation method thereof | |
| CN103638296A (en) | Application of traditional Chinese medicine for treating coronary heart disease | |
| CN104399053A (en) | Drug for treating schizophrenia and preparation method | |
| CN105770520A (en) | Medicine preparation used for treating coronary heart disease and application thereof | |
| CN105343741A (en) | Traditional Chinese medicine for treating thyroid tumor and preparation method of traditional Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160303 Address after: 100085 B5-1-506 room, 5 floor, No. 28 information road, Beijing, Haidian District Patentee after: Saiertaihe Biomedicine Tech Co., Ltd., Beijing Address before: 050600 Hebei province Xingtang County line Tang town of West erduoyan No. 4 Patentee before: Wang Tongzheng |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110504 Termination date: 20160725 |